Interleukin‐33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancer

BACKGROUND: Cetuximab is used for colorectal cancer (CRC) treatment. However, the early biomarker of treatment efficacy of cetuximab has not been identified. METHODS: After 1 year of cetuximab treatment, patients were divided into an effective group and an ineffective group. The interleukin‐33 (IL‐3...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xujun, Bi, Kefan, Tu, Xiaoxuan, Zhang, Qiong, Cao, Qingyi, Liang, Yan, Zeng, Ping, Wang, Lin, Liu, Tianxing, Fang, Weijia, Diao, Hongyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633246/
https://www.ncbi.nlm.nih.gov/pubmed/34664425
http://dx.doi.org/10.1002/cam4.4331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633246/
https://www.ncbi.nlm.nih.gov/pubmed/34664425
http://dx.doi.org/10.1002/cam4.4331

Ejemplares similares